Compass Pathways Teams Up with Osmind to Prepare Clinics for Psychedelic Care
Compass Pathways plc, a biotechnology company focused on expanding access to evidence-based mental health innovations, has announced a strategic collaboration with Osmind, a platform that supports a large network of interventional psychiatry practices across the United States. This partnership is designed to explore and prepare independent clinics—particularly small- to medium-sized practices—for the potential introduction and delivery of psychedelic-assisted treatments, pending regulatory approval.
The collaboration reflects a growing recognition within the mental health field that innovative therapies, including those involving psychedelic compounds, will require not only scientific validation but also practical, scalable systems for real-world implementation. By working together, Compass Pathways and Osmind aim to better understand how these treatments could be integrated into everyday clinical settings, particularly those that operate independently and may lack the infrastructure of larger healthcare systems.
At the center of this initiative is COMP360, Compass Pathways’ investigational psilocybin-based therapy currently being studied for treatment-resistant depression and other mental health conditions. While clinical trials continue to evaluate its safety and effectiveness, Compass is already taking steps to ensure that, if approved by regulators such as the U.S. Food and Drug Administration (FDA), the therapy can be delivered responsibly and effectively in diverse healthcare environments.
Osmind brings significant expertise to this collaboration through its extensive network of more than 1,000 clinics specializing in interventional psychiatry. These clinics represent one of the largest coordinated groups of practices focused on advanced mental health treatments, including therapies like transcranial magnetic stimulation (TMS) and ketamine-based interventions. Osmind provides these clinics with tailored software, operational support, and data-driven tools that help clinicians manage their practices efficiently while maintaining high standards of patient care.
A key challenge in introducing new treatments—especially those as complex as psychedelic-assisted therapies—is the operational burden placed on providers. Independent psychiatry practices often face constraints related to staffing, training, regulatory compliance, and infrastructure. Unlike large hospital systems, these clinics may not have the resources to quickly adopt new treatment models without significant support. This collaboration seeks to address those barriers by identifying practical solutions that enable clinics to integrate innovative therapies without compromising their independence or financial sustainability.
By combining Osmind’s deep understanding of practice management with Compass Pathways’ scientific and clinical expertise, the partnership aims to develop frameworks that support safe, scalable, and patient-centered care. This includes examining the clinical workflows required for psychedelic treatments, such as patient screening, preparation, administration, and follow-up care. It also involves understanding the physical and logistical requirements of delivering such therapies, which often differ significantly from traditional psychiatric treatments.
Another important aspect of the collaboration is the use of real-world evidence. Osmind’s platform collects and analyzes data from its network of clinics, providing valuable insights into how treatments perform outside of controlled clinical trials. This data can help inform best practices, identify potential challenges, and guide the development of standardized protocols for future implementation. By leveraging these insights, Compass Pathways can better anticipate the needs of clinicians and patients, ensuring that new therapies are both effective and accessible.
Dr. Steve Levine, Chief Patient Officer at Compass Pathways, emphasized the importance of preparing for real-world delivery early in the development process. He noted that a central goal for the company is to ensure that COMP360, if approved, can be administered safely and effectively in the settings where patients typically receive care. Through the collaboration with Osmind, Compass aims to learn directly from practicing clinicians and support them in building the capabilities needed to offer psychedelic treatments responsibly.
From Osmind’s perspective, the partnership represents an opportunity to address longstanding gaps in the adoption of innovative mental health treatments. According to Jimmy Qian, Co-Founder and President of Osmind, independent psychiatry practices serve the majority of patients but have historically been underserved when it comes to integrating new therapies. High operational complexity, regulatory uncertainty, and resource limitations have often made it difficult for these clinics to adopt cutting-edge treatments.
Qian highlighted that by combining Osmind’s operational expertise with Compass Pathways’ scientific leadership, the collaboration can help bridge this gap. The goal is to create practical, scalable models that align patient safety, clinical excellence, and accessibility with the realities of running an independent practice. This includes ensuring that clinicians have the tools, training, and support they need to deliver treatments effectively while maintaining the financial viability of their practices.
The collaboration also reflects a broader shift in the mental health landscape toward more personalized and innovative approaches to care. As research into psychedelic-assisted therapies continues to advance, there is increasing interest in how these treatments can address conditions that have proven difficult to treat with conventional methods. However, translating scientific breakthroughs into widespread clinical practice requires careful planning, collaboration, and a deep understanding of the healthcare ecosystem.
By focusing on community-based settings, Compass Pathways and Osmind are acknowledging that the future of mental health care will depend not only on major institutions but also on the network of independent providers who serve patients on a daily basis. These clinics are often the first point of contact for individuals seeking help, making them critical to the successful adoption of new therapies.
Ultimately, this partnership aims to lay the groundwork for a future in which psychedelic treatments, if approved, can be delivered in a way that is safe, effective, and accessible to those who need them most. By addressing the operational, clinical, and infrastructure challenges ahead of time, Compass Pathways and Osmind hope to ensure that innovation in mental health care translates into real-world impact.
As the field continues to evolve, collaborations like this one will play a crucial role in bridging the gap between research and practice. By bringing together expertise in science, technology, and clinical operations, Compass Pathways and Osmind are taking a proactive approach to shaping the future of mental health treatment—one that prioritizes both innovation and practical implementation.
About Compass Pathways
Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational COMP360 synthetic psilocybin treatment, potentially a first in class treatment. COMP360 has Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD).
Compass is headquartered in London, UK, with offices in New York in the US. We envision a world where mental health means not just the absence of illness but the ability to thrive.
